A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

por Nemunaitis, John J, Small, Karen A, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Statkevich, Paul, Yao, Siu-Long, Bannerji, Rajat
Publicado 2013

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus

por Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi
Publicado 2016

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

por Jagannath, Sundar, Laubach, Jacob, Wong, Ellice, Stockerl‐Goldstein, Keith, Rosenbaum, Cara, Dhodapkar, Madhav, Jou, Ying‐Ming, Lynch, Mark, Robbins, Michael, Shelat, Suresh, Anderson, Kenneth C., Richardson, Paul G.
Publicado 2018

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

por Gojo, Ivana, Sadowska, Mariola, Walker, Alison, Feldman, Eric J., Iyer, Swaminathan Padmanabhan, Baer, Maria R., Sausville, Edward A., Lapidus, Rena G., Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Poon, Jennifer, Small, Karen, Bannerji, Rajat
Publicado 2013

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

por Dimopoulos, Meletios A., Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S., Richardson, Paul G., Popa McKiver, Mihaela, Jou, Ying-Ming, Yao, David, Das, Prianka, San-Miguel, Jesús
Publicado 2023

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

por Mita, Monica M, Mita, Alain C, Moseley, Jennifer L, Poon, Jennifer, Small, Karen A, Jou, Ying-Ming, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Statkevich, Paul, Sankhala, Kamelesh K, Sarantopoulos, John, Cleary, James M, Chirieac, Lucian R, Rodig, Scott J, Bannerji, Rajat, Shapiro, Geoffrey I
Publicado 2017

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

por Richter, Joshua, Ailawadhi, Sikander, Lee, Hans C., Hardin, James W., Terebelo, Howard R., Abonour, Rafat, Wagner, Lynne I., Durie, Brian G.M., Omel, James L., Narang, Mohit, Toomey, Kathleen, Rifkin, Robert M., Gasparetto, Cristina J., Yu, Edward, Anand, Jasmeet, Liu, Liang, Jou, Ying-Ming, Jagannath, Sundar
Publicado 2022

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

por Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., Richardson, Paul G.
Publicado 2020